| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| GRI Bio, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 43,222 | $29,704 | $0.6857 | 18 Sep 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GRI | GRI Bio, Inc. | 18 Sep 2025 | 1 | $0 | 4 | Chief Financial Officer | 22 Sep 2025, 16:06 |
| GRI | GRI Bio, Inc. | 26 Aug 2025 | 1 | $0 | 4 | Chief Financial Officer | 27 Aug 2025, 08:24 |
| GRI | GRI Bio, Inc. | 23 Jan 2025 | 1 | +$29,704 | 4 | Chief Financial Officer | 24 Jan 2025, 17:58 |
| WINT | WINDTREE THERAPEUTICS INC /DE/ | 08 Jan 2025 | 0 | $0 | 3 | Director | 14 Jan 2025, 16:17 |
| GRI | GRI BIO, Inc. | 22 Sep 2023 | 1 | +$126,666 | 4 | Chief Financial Officer | 26 Sep 2023, 17:08 |
| GRI | Vallon Pharmaceuticals, Inc. | 15 Feb 2022 | 1 | +$281,500 | 4 | Chief Financial Officer | 01 Mar 2022, 16:03 |
| GRI | Vallon Pharmaceuticals, Inc. | 02 Jun 2021 | 3 | +$25,175 | 4 | Chief Financial Officer | 04 Jun 2021, 16:06 |
| GRI | Vallon Pharmaceuticals, Inc. | 14 May 2021 | 1 | $0 | 4 | Chief Financial Officer | 18 May 2021, 16:07 |
| GRI | Vallon Pharmaceuticals, Inc. | 11 May 2021 | 0 | $0 | 3 | Chief Financial Officer | 18 May 2021, 16:05 |